Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2021; 11(11):5464-5490. doi:10.7150/thno.54822 This issue Cite

Review

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma

Fan-Hua Kong1,2, Qi-Fa Ye2, Xiong-Ying Miao1, Xi Liu3, Si-Qi Huang4, Li Xiong1, Yu Wen1✉, Zi-Jian Zhang1✉

1. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
2. Institute of Hepatobiliary Diseases of Wuhan University, Transplant Centre of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei, China.
3. Department of Gastrointestinal Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
4. Department of Integrated Traditional Chinese & Western Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

✉ Corresponding authors: Zijian Zhang, Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China. E-mail: 178211082edu.cn; Yu Wen, Department of General Surgery, The Second Xiangya Hospita More

Citation:
Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021; 11(11):5464-5490. doi:10.7150/thno.54822. https://www.thno.org/v11p5464.htm
Other styles

File import instruction

Abstract

Graphic abstract

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the leading causes of cancer-related death worldwide. Advanced HCC displays strong resistance to chemotherapy, and traditional chemotherapy drugs do not achieve satisfactory therapeutic efficacy. Sorafenib is an oral kinase inhibitor that inhibits tumor cell proliferation and angiogenesis and induces cancer cell apoptosis. It also improves the survival rates of patients with advanced liver cancer. However, due to its poor solubility, fast metabolism, and low bioavailability, clinical applications of sorafenib have been substantially restricted. In recent years, various studies have been conducted on the use of nanoparticles to improve drug targeting and therapeutic efficacy in HCC. Moreover, nanoparticles have been extensively explored to improve the therapeutic efficacy of sorafenib, and a variety of nanoparticles, such as polymer, lipid, silica, and metal nanoparticles, have been developed for treating liver cancer. All these new technologies have improved the targeted treatment of HCC by sorafenib and promoted nanomedicines as treatments for HCC. This review provides an overview of hot topics in tumor nanoscience and the latest status of treatments for HCC. It further introduces the current research status of nanoparticle drug delivery systems for treatment of HCC with sorafenib.

Keywords: Hepatocellular carcinoma, Sorafenib, Nanomaterials, Nanoparticles, Nanomedicine.

Citation styles

APA
Kong, F.H., Ye, Q.F., Miao, X.Y., Liu, X., Huang, S.Q., Xiong, L., Wen, Y., Zhang, Z.J. (2021). Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics, 11(11), 5464-5490. https://doi.org/10.7150/thno.54822.

ACS
Kong, F.H.; Ye, Q.F.; Miao, X.Y.; Liu, X.; Huang, S.Q.; Xiong, L.; Wen, Y.; Zhang, Z.J. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021, 11 (11), 5464-5490. DOI: 10.7150/thno.54822.

NLM
Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021; 11(11):5464-5490. doi:10.7150/thno.54822. https://www.thno.org/v11p5464.htm

CSE
Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. 2021. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 11(11):5464-5490.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use